Correction: Population-wide impact of long-term use of aspirin and the risk for cancer (JAMA Oncology (2016) 2:6 (762-769) DOI: 10.1001/jamaoncol.2015.6396);Population-wide impact of long-term use of aspirin and the risk for cancer

JAMA Oncology

Volumn 2, Issue 6, 2016, Pages 762-769

  Cao, Yin ^a,b   Nishihara, Reiko ^a,b   Wu, Kana ^a   Wang, Molin ^a   Ogino, Shuji ^a,b   Willett, Walter C ^a,b   Spiegelman, Donna ^a   Fuchs, Charles S ^b   Giovannucci, Edward L ^a,b   Chan, Andrew T ^b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID;

ADULT; AGED; COLORECTAL NEOPLASMS; FEMALE; FOLLOW UP; GASTROINTESTINAL NEOPLASMS; HUMAN; MALE; META ANALYSIS; MIDDLE AGED; PATHOLOGY; RISK ASSESSMENT;

ADULT; AGED; ASPIRIN; COLORECTAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL NEOPLASMS; HUMANS; MALE; MIDDLE AGED; RISK ASSESSMENT;

EID: 85010679719     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2019.0220     Document Type: Erratum

References (49)

1. Rothwell PM, Price JF, Fowkes FG, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet. 2012;379 (9826):1602-1612.
2. Cook NR, Lee IM, Zhang SM, MoorthyMV, Buring JE. Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial. Ann Intern Med. 2013;159(2):77-85.
3. Jacobs EJ, Thun MJ, Bain EB, Rodriguez C, Henley SJ, Calle EE. A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst. 2007;99(8): 608-615.
4. Algra AM, Rothwell PM. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol. 2012;13(5):518-527.
5. Bosetti C, Rosato V, Gallus S, Cuzick J, La Vecchia C. Aspirin and cancer risk: a quantitative review to 2011. Ann Oncol. 2012;23(6):1403-1415.
6. Cuzick J, Thorat MA, Bosetti C, et al. Estimates of benefits and harms of prophylactic use of aspirin in the general population. Ann Oncol. 2015;26(1):47-57.
7. US Preventive Services Task Force. Routine aspirin or nonsteroidal anti-inflammatory drugs for the primary prevention of colorectal cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2007;146(5):361-364.
8. Chubak J, Kamineni A, Buist DSM, Anderson ML, Whitlock EP. Aspirin Use for the Prevention of Colorectal Cancer: An Updated Systematic Evidence Review for the US Preventive Services Task Force. Rockville, MD: Agency for Healthcare Research and Quality; 2015.
9. Dehmer SP, Maciosek MV, Flottemesch TJ. Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: A Decision Analysis: Technical Report. Rockville, MD: Agency for Healthcare Research and Quality; 2015.
10. US Preventive Services Task Force. Draft recommendation statement: aspirin to prevent cardiovascular disease and cancer. http://www.uspreventiveservicestaskforce.org/Page /Document/draft-recommendation-statement /aspirin-to-prevent-cardiovascular-disease-and -cancer. September 2015. Accessed November 2, 2015.
11. Chan AT, Ladabaum U. Where do we stand with aspirin for the prevention of colorectal cancer? the USPSTF recommendations. Gastroenterology. 2016;150(1):14-18.
12. Whitlock EP,Williams SB, Burda BU, Feightner A, Beil T. Aspirin Use in Adults: Cancer, All-Cause Mortality, and Harms: A Systematic Evidence Review for the US Preventive Services Task Force. Rockville, MD: Agency for Healthcare Research and Quality; 2015.
13. Sutcliffe P, Connock M, Gurung T, et al. Aspirin for prophylactic use in the primary prevention of cardiovascular disease and cancer: a systematic review and overview of reviews. Health Technol Assess. 2013;17(43):1-253.
14. Nishihara R,Wu K, Lochhead P, et al. Long-term colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med. 2013;369(12):1095-1105.
15. Manson JE, Stampfer MJ, Colditz GA, et al. A prospective study of aspirin use and primary prevention of cardiovascular disease in women. JAMA. 1991;266(4):521-527.
16. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, WillettWC. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med. 1994;121(4):241-246.
17. Rich-Edwards JW, Corsano KA, Stampfer MJ. Test of the National Death Index and Equifax Nationwide Death Search. Am J Epidemiol. 1994; 140(11):1016-1019.
18. Stampfer MJ,WillettWC, Speizer FE, et al. Test of the National Death Index. Am J Epidemiol. 1984;119(5):837-839.
19. Wilson KM, Kasperzyk JL, Rider JR, et al. Coffee consumption and prostate cancer risk and progression in the Health Professionals Follow-up Study. J Natl Cancer Inst. 2011;103(11):876-884.
20. McCullough ML, Feskanich D, Stampfer MJ, et al. Diet quality and major chronic disease risk in men and women: moving toward improved dietary guidance. Am J Clin Nutr. 2002;76(6):1261-1271.
21. Chiuve SE, Fung TT, Rimm EB, et al. Alternative dietary indices both strongly predict risk of chronic disease. J Nutr. 2012;142(6):1009-1018.
22. Gay LJ, Felding-Habermann B. Contribution of platelets to tumour metastasis. Nat Rev Cancer. 2011;11(2):123-134.
23. American Cancer Society. Facts and Figures. Atlanta, GA: American Cancer Society; 2015.
24. Edwards BK,Ward E, Kohler BA, et al. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2010; 116(3):544-573.
25. US Department of Health and Human Services, Centers for Disease Control and Prevention. Health, United States, 2014:With Special Feature on Adults Aged 55-64. Hyattsville, MD: National Center for Health Statistics; 2015.
26. US Census Bureau. Age and Sex Composition: 2010.Washington, DC: US Census Bureau; 2011.
27. Chan AT, Giovannucci EL,Meyerhardt JA, Schernhammer ES, Curhan GC, Fuchs CS. Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA. 2005;294(8):914-923.
28. Chan AT, Giovannucci EL,Meyerhardt JA, Schernhammer ES,Wu K, Fuchs CS. Aspirin dose and duration of use and risk of colorectal cancer in men. Gastroenterology. 2008;134(1):21-28.
29. Ruder EH, Laiyemo AO, Graubard BI, Hollenbeck AR, Schatzkin A, Cross AJ. Non-steroidal anti-inflammatory drugs and colorectal cancer risk in a large, prospective cohort. Am J Gastroenterol. 2011;106(7):1340-1350.
30. Rothwell PM, Wilson M, Elwin CE, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet. 2010;376(9754):1741-1750.
31. Yang P, Zhou Y, Chen B, et al. Aspirin use and the risk of gastric cancer: ameta-analysis. Dig Dis Sci. 2010;55(6):1533-1539.
32. Abnet CC, Freedman ND, Kamangar F, Leitzmann MF, Hollenbeck AR, Schatzkin A. Non-steroidal anti-inflammatory drugs and risk of gastric and oesophageal adenocarcinomas: results from a cohort study and ameta-analysis. Br J Cancer. 2009;100(3):551-557.
33. Farrell B, Godwin J, Richards S,Warlow C. The United Kingdom Transient Ischaemic Attack (UK-TIA) Aspirin Trial: final results. J Neurol Neurosurg Psychiatry. 1991;54(12):1044-1054.
34. Zhang X, Smith-Warner SA, Collins LC, Rosner B, WillettWC, Hankinson SE. Use of aspirin, other nonsteroidal anti-inflammatory drugs, and acetaminophen and postmenopausal breast cancer incidence. J Clin Oncol. 2012;30(28):3468-3477.
35. Feskanich D, Bain C, Chan AT, Pandeya N, Speizer FE, Colditz GA. Aspirin and lung cancer risk in a cohort study of women: dosage, duration and latency. Br J Cancer. 2007;97(9):1295-1299.
36. Dhillon PK, Kenfield SA, Stampfer MJ, Giovannucci EL, Chan JM. Aspirin use after a prostate cancer diagnosis and cancer survival in a prospective cohort. Cancer Prev Res (Phila). 2012;5 (10):1223-1228.
37. Rothwell PM, Fowkes FGR, Belch JFF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet. 2011;377(9759):31-41.
38. Rothwell PM, Wilson M, Price JF, Belch JFF, Meade TW, Mehta Z. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet. 2012; 379(9826):1591-1601.
39. Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. JAMA. 2009;302(6):649-658.
40. Ye XF,Wang J, ShiWT, He J. Relationship between aspirin use after diagnosis of colorectal cancer and patient survival: ameta-analysis of observational studies. Br J Cancer. 2014;111(11):2172-2179.
41. HolmesMD, ChenWY, Li L, Hertzmark E, Spiegelman D, Hankinson SE. Aspirin intake and survival after breast cancer. J Clin Oncol. 2010;28 (9):1467-1472.
42. Jacobs EJ, Newton CC, Stevens VL, Campbell PT, Freedland SJ, Gapstur SM. Daily aspirin use and prostate cancer-specific mortality in a large cohort of men with nonmetastatic prostate cancer. J Clin Oncol. 2014;32(33):3716-3722.
43. Thun MJ, Jacobs EJ, Patrono C. The role of aspirin in cancer prevention. Nat Rev Clin Oncol. 2012;9(5):259-267.
44. Chan AT, Arber N, Burn J, et al. Aspirin in the chemoprevention of colorectal neoplasia: an overview. Cancer Prev Res (Phila). 2012;5(2):164-178.
45. Gala MK, Chan AT. Molecular pathways: aspirin andWnt signaling-a molecularly targeted approach to cancer prevention and treatment. Clin Cancer Res. 2015;21(7):1543-1548.
46. Drew DA, Cao Y, Chan AT. Aspirin and colorectal cancer: the promise of precision chemoprevention. Nat Rev Cancer. In press.
47. Nan H, Hutter CM, Lin Y, et al; CCFR; GECCO. Association of aspirin and NSAID use with risk of colorectal cancer according to genetic variants. JAMA. 2015;313(11):1133-1142.
48. Nishihara R, Lochhead P, Kuchiba A, et al. Aspirin use and risk of colorectal cancer according to BRAF mutation status. JAMA. 2013;309(24): 2563-2571.
49. Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med. 2007;356(21):2131-2142.